Statements from the 15th International Symposium on HIV and Emerging Infectious Diseases (ISHEID), Toulon, France, May 28-30, 2008

HIV Clinical Trials

Volumn 9, Issue 5, 2008, Pages 348-365

  Haubrich, Richard ^a   Soriano, Vincent ^b   Lafeuillade, Alain ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c GENERAL HOSPITAL   (France)

Author keywords

Antiretroviral strategies; H V; Hepatitis B; Hepatitis C; Integrase inhibitor; New drugs; Preexposure prophylaxis; Vaccine; Vicriviroc

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ATAZANAVIR; BEVIRIMAT; DARUNAVIR; EFAVIRENZ; ELVITEGRAVIR; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; ETRAVIRINE; FIBRIC ACID DERIVATIVE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBALIZUMAB; INTEGRASE INHIBITOR; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; PEGINTERFERON; PLACEBO; PROTEINASE INHIBITOR; RALTEGRAVIR; RIBAVIRIN; RIFAMPICIN; RILPIVIRINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; UNINDEXED DRUG; VICRIVIROC;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; AREA UNDER THE CURVE; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; GASTROINTESTINAL SYMPTOM; HALF LIFE TIME; HEPATITIS; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; INFECTION PREVENTION; LIPID BLOOD LEVEL; LIVER FIBROSIS; LIVER TOXICITY; MENTAL DISEASE; MIXED INFECTION; MONKEY DISEASE; MONOTHERAPY; NAUSEA; NEUROLOGIC DISEASE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEXUAL TRANSMISSION; SIDE EFFECT; SIMIAN IMMUNODEFICIENCY VIRUS; TRIACYLGLYCEROL BLOOD LEVEL; TUBULAR DYSFUNCTION; UNSPECIFIED SIDE EFFECT; VERTICAL TRANSMISSION; VIRUS LOAD; VIRUS MUTATION;

AIDS VACCINES; ANIMALS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COMMUNICABLE DISEASES, EMERGING; CONGRESSES AS TOPIC; FRANCE; HEPACIVIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HIV; HIV INFECTIONS; HUMANS;

EID: 57149102497     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct0905-348     Document Type: Review

References (80)

1. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. January 29; www.aidsinfo.nih.gov. Accessed March 18, 2008.
2. Hirsch MS, Brun-Vezinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society USA Panel. Clin Infect Dis. 2003;37(1):113-128.
3. European guidelines for the clinical management and treatment of HIV-infected adults in Europe. AIDS. 2003; 17(Suppl 2):S3-26.
4. Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA. 2004;292(2):251-265.
5. Little S, Koelsch K, Ignacio C, et al. Persistence of transmitted drug-resistant virus among subjects with primary HIV infection deferring antiretroviral therapy. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2004; San Francisco, CA. Abstract 36LB.
6. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 2002;347(6):385-394.
7. Weinstock HS, Zaidi I, Heneine W, et al. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis. 2004; 189(12):2174-2180.
8. Descamps D, Chaix ML, Andre P, et al. French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001-2002. J Acquir Immune Defic Syndr. 2005;38(5):545-552.
9. Novak RM, Chen L, MacArthur RD, et al. Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: Implications for routine resistance screening before initiation of antiretroviral therapy. Clin Infect Dis. 2005;40(3):468-474.
10. Wegner SA, Brodine SK, Mascola JR, et al. Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naive HIV-1 infected US military personnel. AIDS. 2000;14(8):1009-1015.
11. Kuritzkes DR, Lalama CM, Ribaudo HJ, et al. Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. J Infect Dis. 2008;197(6):867-870.
12. Rocha Silva S, Piñeiro C, Xerinda S, Ferreira D, Marques R, Sarmento A. Prevalence of resistance mutations in chronic HIV-1-infected anti-retroviral naive patients. In: Program and Abstracts of the 15th ISHEID; May 28-30, 2008; Toulon, France. abstract PA1/09. Reprinted in HIV Clin Trials. 2008;9(Suppl 1):19.
13. 3. J Infect Dis. 2005;192(6):950-957.
14. Riddler S, Haubrich R, DiRienzo G, et al. A randomized comparison of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial treatment of HIV-1 infection - ACTG 5142. N Engl J Med. 2008;358(20):2095-2106.
15. Sabin CA, Worm SW, Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: A multi-cohort collaboration. Lancet. 2008;371(9622):1417-1426.
16. Molina J, Andrade-Villanueva J, Echevarria J, et al. Efficacy and safety of boosted once once-daily atazanavir and twice twice-daily lopinavir regimens in treatment-naïve HIV-1 infected subjects. In: Program and abstracts of the 15th Conference on Retroviruses and Opportunistic Infections; February 3-6, 2008; Boston, MA. Abstract 37.
17. De Jesus E, Ortiz R, Khanlou H, et al. Efficacy and safety of darunavir/ ritonavir versus lopinavir/ritonavir in ARV treatment-naïve HIV-1-infected patients at week 48: ARTEMIS (TMC114-C211) In: Program and abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 17-20, 2007; Chicago, IL. Abstract H-718B.
18. Calvez V, Dierynck I, de Meyer S, et al. Efficacy of DRV/r in the randomized, controlled, Phase III ARTEMIS Trial in treatment-naïve, HIV-1-infected patients is independent of HIV-1 subtype. In: Program and abstracts of the 15th ISHEID; May 28-30, 2008; Toulon, France. Abstract PD5. Reprinted in HIV Clin Trials. 2008;9(Suppl 1):15.
19. Cooper D. Integrase inhibitors. In: Program and abstracts of the 15th ISHEID; May 28-30, 2008; Toulon, France; p. 28.
20. Cooper D, Gatell J, Rockstroh J, et al. 48-week results from BENCHMRK-1, a Phase III study of raltegravir (RAL) in patients failing antiretroviral therapy (ART) with triple-class resistant HIV-1. In: Program and Abstracts of the 15th Conference on Retroviruses and Opportunistic Infections; February 3-6, 2008; Boston, MA. Abstract 788.
21. Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med. 2008;359(4):355-365.
22. Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 2008;359(4):339-354.
23. Gulick R, Haas D, Collier A, et al. Long-term follow-up of treatment-experienced patients on vicriviroc (VCV). In: Program and abstracts of the 15th ISHEID; May 28-30, 2008; Toulon, France. Abstract PS1/6. Reprinted in HIV Clin Trials. 2008;9(Suppl 1):4.
24. Opravil M, Dunkel L, McCarthy M, Case N, Mak C. Vicriviroc (VCV) is a potent QD CCR5 antagonist with predictable pharmacokinetics in a PI/ r-containing regimen. In: Program and abstracts of the 15th ISHEID; May 28-30, 2008; Toulon, France. Abstract PD6. Reprinted in HIV Clin Trials. 2008;9(Suppl 1):14.
25. De Smedt G, Katlama C, Trottier B, et al. Pooled 48-week analysis of DUET-1 and DUET-2: Durable efficacy and safety results of etravirine (TMC125; ETR) in treatment-experienced HIV-infected patients. In: Program and abstracts of the 15th ISHEID; May 28-30, 2008; Toulon, France. Abstract PS1/5. Reprinted in HIV Clin Trials. 2008; 9(Suppl 1):3.
26. Gulick R. New Antiretroviral drugs in the pipeline. In: Program and abstracts of the 15th ISHEID; May 28-30, 2008; Toulon, France; p. 29.
27. Law MG, Friis-Moller N, El-Sadr WM, et al. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: Comparison with observed events in the D:A:D Study. HIV Med. 2006;7:218-230.
28. Sekar VJ, Spinosa-Guzman S, Marien K, et al. Pharmacokinetic drug-drug interaction between the new HIV protease inhibitor darunavir (TMC114) and the lipid-lowering agent pravastatin. In: Program and abstracts of the 8th International Workshop on Pharmacology of HIV Therapy; April 16-18, 2007; Budapest, Hungary. Abstract 55.
29. Gatell J, Salmon-Ceron D, Lazzarin A, et al. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: The SWAN Study (AI424-097) 48-week results. Clin Infect Dis. 2007;44(11):1484-1492.
30. van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: A randomised open-label trial, the 2NN Study. Lancet. 2004;363(9417):1253-1263.
31. Gallant JE, De Jesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354:251-260.
32. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: A 3-year randomized trial. JAMA. 2004;292(2):191-201.
33. Soriano V, Puoti M, Garcia-Gasco P, et al. Antiretroviral drugs and liver injury. AIDS. 2008;22:1-13.
34. Barreiro P. Novel mechanisms of antiretroviral liver toxicity. In: Program and abstracts of the 15th ISHEID; May 28-30, 2008; Toulon, France; p. 32.
35. Maida I, Nuñez M, Rios MJ, et al. Severe liver disease associated with prolonged exposure to antiretroviral drugs. J Acquir Immune Defic Syndr. 2006;42:177-182.
36. Mallet V, Blanchard P, Verkarre V, et al. Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients. AIDS. 2007;21:187-192.
37. Schiano T, Kotler D, Ferran E, Fiel M. Hepatoportal sclerosis as a cause of non-cirrhotic portal hypertension in patients with HIV. Am J Gastroenterol. 2007;102:2356-2540.
38. Maida I, García-Gascó P, Sotgiu G, et al. Antiretroviral-associated portal hypertension: A new clinical condition? Prevalence, predictors and outcome. Antivir Ther. 2008; 13:103-107.
39. Balagopal A, Philp F, Astemborski J, et al. Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology. In press.
40. Brenchley J, Price D, Schacker T, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12:1365-1371.
41. Manfredi R, Calza L. Nevirapine administration in HIV-infected pregnant women with a proportionally elevated CD4+ lymphocyte count - hepatic tolerability and safety considerations. In: Program and abstracts of the 15th ISHEID; May 28-30, 2008; Toulon, France. Abstract PB3/07. Reprinted in HIV Clin Trials. 2008;9(Suppl 1):36.
42. De Lazzari E, León A, Arnaiz JA, et al. Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts. HIV Med. 2008; 9:221-226.
43. Stern J, Robinson P, Love J, Lanes S, Imperiale M, Mayers D. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr. 2003;34(Suppl 1):21-33.
44. Barreiro P, Rodríguez-Novoa S, Labarga P, et al. Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C. J Infect Dis. 2007;195:973-979.
45. Nichols W, Steel H, Bonny T, et al. Hepatotoxicity observed in clinical trials of aplaviroc (GW873140). Antimicrob Agents Chemother. 2008;52:858-865.
46. Fatkenheuer G, Hoffmann C, Slim J, Rouzier R, Schurmann D. Administration of the CCR5 antagonist Vicriviroc to patients with HIV/ HCV coinfection is safe and well tolerated. In: Program and abstracts of the 15th ISHEID; May 28-30, 2008; Toulon, France. Abstract PS3/4. Reprinted in HIV Clin Trials. 2008;9(Suppl 1):9.
47. Fiogbe A, Zannou M, Sehonou J, Bashi J, Houngbe F, Kodjoh N. HIV/HBV co-infection among patients treated by HAART in Benin. In: Program and abstracts of the 15th ISHEID; May 28-30, 2008; Toulon, France. Abstract PA4/02. Reprinted in HIV Clin Trials. 2008;9(Suppl 1):22.
48. Martinez-Peralta L, Trinks J, Cuestas M, et al. Differential subtypes of HIV and hepatitis B virus are prevalent among injecting drug users and men who have sex with men in Buenos Aires, Argentina. In: Program and abstracts of the 15th ISHEID; May 28-30, 2008; Toulon, France. Abstract PC2/03]. Reprinted in HIV Clin Trials. 2008;9(Suppl 1):68.
49. Thio C, Seaberg E, Skolasky R, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet. 2002;360:1921-1926.
50. Soriano V, Vispo E, Bottecchia M, et al. Management of hepatitis B virus co-infection and off antiretroviral therapy. Curr HIV/AIDS Rep. 2008;5:86-93.
51. McMahon M, Jilek B, Brennan T, et al. The HBV drug entecavir - effects on HIV-1 replication and resistance. N Engl J Med. 2007;356:2614-2621.
52. Labarga P. Renal dysfunction and antiretroviral therapy - proximal tubulopathy. In: Program and abstracts of the 15th ISHEID; May 28-30, 2008; Toulon, France; p. 30.
53. Palacios R, Mata R, Hidalgo A, et al. Very low prevalence and no clinical significance of occult hepatitis B in a cohort of HIV-infected patients with isolated anti-HBc seropositivity - the BHOI study. In: Program and abstracts of the 15th ISHEID; May 28-30, 2008; Toulon, France. Abstract PS4/2. Reprinted in HIV Clin Trials. 2008;9(Suppl 1):10.
54. Le Gal F, Abdou M, Brichler S, Allour C, Gordien E, Deny P. The increasing prevalence of hepatitis delta - African clades in France confirms a deltavirus genus of at least 8 major clades. In Program and abstracts of the 15th ISHEID, May 28-30, 2008; Toulon, France. Abstract PS4/3. Reprinted in HIV Clin Trials. 2008;9(Suppl 1):10.
55. Sheldon J, Ramos B, Toro C, et al. Does treatment of hepatitis B virus (HBV) infection reduce hepatitis delta virus (HDV) replication in HIV-HBV-HDV-coinfected patients? Antivir Ther. 2008;13:97-102.
56. Gotz H, van Doornum G, Niesters H, den Hollander J, Thio H, de Zwart O. A cluster of acute C virus infection among men who have sex with men - results from contact tracing and public health implications. AIDS. 2005;19:969-974.
57. Ghosn J, Pierre-Francois S, Thibault V, et al. Acute hepatitis C in HIV-infected men who have sex with men. HIV Med. 2004;5:615-624.
58. Gilleece Y, Browne R, Asboe D, et al. Transmission of hepatitis C virus among HIV-positive homosexual men and response to a 24 week course of pegylated interferon and ribavirin. J Acquir Immune Defic Syndr. 2005;40:41-46.
59. Luetkemeyer A, Hare C, Stansell J, et al. Clinical presentation and course of acute hepatitis C infection in HIV-infected patients. J Acquir Immune Defic Syndr. 2006;41:31-36.
60. Vogel M, Nattermann J, Baumgarten A, et al. Pegylated interferon-alpha for the treatment of sexually transmitted acute hepatitis C in HIV-infected individuals. Antivir Ther. 2006;11:1097-1101.
61. Danta M, Brown D, Bhagani S, et al. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS. 2007; 21:983-991.
62. Nelson M. Acute HCV infection. In: Program and abstracts of the 15th ISHEID; May 28-30, 2008; Toulon, France; p. 14.
63. Marx M, Marugabel K, Tarwater P, et al. Association of hepatitis C virus infection with sexual exposure in southern India. Clin Infect Dis. 2003;37:524-520.
64. Buchacz K, Patel P, Taylor M, et al. Syphilis increase HIV viral load and decrease CD4 cell counts in HIV-infected patients with new syphilis infections. AIDS. 2004;18:2075-2079.
65. Simms I, Fenton K, Ashton M, et al. The re-emergence of syphilis in the United Kingdom: The new epidemic phases. Sex Transm Dis. 2005;32:220-226.
66. Zellan J, Augenbraun M. Syphilis in the HIV infected patient: An up to date on epidemiology, diagnosis, and management. Curr HIV/AIDS Rep. 2004;1:142-147.
67. Brewer D, Golden M, Handsfield H. Unsafe sexual behaviour and correlates of risk in a probability sample of men who have sex with men in the era of highly active antiretroviral therapy. Sex Transm Dis. 2006;33:250-255.
68. Vispo E, Martinez-Alarcon J, Poveda E, Toro C, Soriano V. Initial spontaneous clearance and re-with a distinct hepatitis C virus genotype leading to chronic hepatitis C in an HIV+ intravenous drug user. AIDS. 2008;22:318.
69. Soriano V, Maida I, Núñez M, et al. Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferon-based therapies. Antivir Ther. 2004;9:987-992.
70. Barreiro P, Labarga P, Martín-Carbonero L, et al. Sustained virological response following HCV therapy is associated with non-progression of liver fibrosis in HCV/HIV-coinfected patients. Antivir Ther. 2006;11:869-877.
71. Halfon P, Carrat F, Bedossa P, et al. Impact of antiviral treatment on non-invasive predictors of liver fibrosis in HIV-HCV coinfected patients: The Fibrovic 2 study-ANRS HC02. In: Program and abstracts of the 15th ISHEID; May 28-30, 2008; Toulon, France. Abstract PS3/1. Reprinted in HIV Clin Trials. 2008;9(Suppl 1):7-8.
72. Poizot-Martin I, Benhaim S, Vion-Dury F, et al. Alfa-fetoprotein combined with ultrasound liver evaluation every 6 months in the screening of hepatocellular carcinoma for HIV/HCV co-infected patients. In: Program and abstracts of the 15th ISHEID; May 28-30, 2008; Toulon, France. Abstract PB4/01. Reprinted in HIV Clin Trials. 2008; 9(Suppl 1):38-39.
73. Soriano V, Puoti M, Sulkowski M, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS. 2007;21:1073-1089.
74. Núñez M, Miralles C, Berdún MA, et al. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: The PRESCO trial. AIDS Res Hum Retroviruses. 2007;23:972-982.
75. Poizot-Martin I, Benhaim S, Drogoul-Vey M, et al. Peginterferon alfa plus ribavirin and HIV-HCV coinfection: Analysis of response rates in routine practice. In: Program and abstracts of the 15th ISHEID; May 28-30, 2008; Toulon, France. Abstract PB6/01. Reprinted in HIV Clin Trials. 2008;9(Suppl 1):43-44.
76. Cacoub P, Carrat F, Bedossa P, et al. Insulin resistance impairs sustained virological response rate to pegylated interferon plus ribavirin in HIV-HCV coinfected patients: HOMAVIC-ANRS HC-02 study. In: Program and abstracts of the 15th ISHEID; May 28-30, 2008; Toulon, France. Abstract PS3/2. Reprinted in HIV Clin Trials. 2008;9(Suppl 1):8.
77. Manfredi R, Calza L. Interferon pegylated plus ribavirin for chronic hepatitis C treatment - a role in the re-activation of severe pulmonary tuberculosis? In: Program and abstracts of the 15th ISHEID; May 28-30, 2008; Toulon, France. Abstract PB7/01. Reprinted in HIV Clin Trials. 2008;9(Suppl 1):44.
78. Vispo E, Barreiro P, Pineda JA, et al. Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir. Antivir Ther. 2008; 13:429-437.
79. De Clerq E, Paxton L. Pre-exposure prophylaxis for HIV infection? In: Program and abstracts of the 15th ISHEID; May 28-30, 2008; Toulon, France; p. 14.
80. Peterson L, Taylor D, Roddy R, et al. Tenofovir disoproxil fumarate for prevention of HIV infection in women: A phase 2, double-blind, randomized, placebo-controlled trial. PLoS Clin Trials. 2007;2(5):e27.